Claims

1. Use of CDB 2914 (Ulipristal), or a metabolite thereof in the manufacture of a medicament for normalizing menstrual bleeding on the long-term in a subject suffering from uterine fibroids whereby the medicament is to be administered before undergone a vascular occlusion method or a thermal related treatment method, wherein the vascular occlusion method is selected from the group comprising uterine artery embolization (UAE) and transvaginal uterine artery embolization and the thermal related treatment method is selected from the group comprising thermal myolysis with laser, percutaneous laser treatment, radiofrequency ablation, cryomyolysis, and magnetic resonance-guided focused ultrasound, wherein the long-term normalization lasts at least 6 months after undergoing said vascular occlusion method or said thermal related method and wherein said metabolite is selected from the group consisting of CDB-3877 and CDB-3236.

2. Use according to claim 1, wherein the menstrual bleeding is normalized when the menstrual blood loss is reduced to < 80ml per menstrual cycle.

3. Use according to claim 1, wherein CDB 2914 (Ulipristal) or a metabolite thereof is to be administered in a dosage of 5 to 20 mg.

4. Use according to claim 3, wherein the dosage of CDB 2914 (Ulipristal), or a metabolite thereof is about 5 mg, about 6 mg, about 7 mg, about 8 mg, about 9 mg, about 10 mg, about 11 mg, about 12 mg, about 13 mg, about 14 mg, about 15 mg, about 16 mg, about 17 mg, about 18 mg, about 19 mg, or about 20 mg.

5. Use according to claim 3 or 4, wherein the dosage of CDB 2914 (Ulipristal), or a metabolite thereof, is about 5 mg.

6. Use according to claim 3 or 4, wherein the dosage of CDB 2914 (Ulipristal), or a metabolite thereof, is about 7 mg.

7. Use according to claim 3 or 4, wherein the dosage of CDB 2914 (Ulipristal), or a metabolite thereof, is about 10 mg.

8. Use according to claims anyone of claims 1 to 7, wherein the subject is a mammal, preferably a human being.

9. Use according to claims anyone of claims 1 to 8, wherein the dosage is a daily dosage.